September 28, 2014 11:05 AM | 1 min read |
The eighth largest investor in Allergan Inc. (NYSE: AGN), joined a group of investors concerned the Botox-maker may seek an acquisition of Salix Pharmaceuticals Ltd. (NYSE: SLXP), in an effort to prevent a $54 billion takeover attempt by Bill Ackman and Valeant Pharmaceuticals International Inc. (NYSE: VRX). Jackson Square Partners Chairman and CIO Jeff Van Harte said Allergan should not complete a deal prior to a December 18 shareholders meeting, according to
Bloomberg
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
.T. Rowe Price Group Inc. (NASDAQ: TROW), Allergan's third-largest shareholder, expressed its opposition on Friday to any Allergan acquisition ahead of the meeting. Allergan rejected a bid in June from Valeant, consisting of $72 in cash and 0.83 Valeant shares for each Allergan share.
Dow Jones reported on September 22 that Allergan was in talks to acquire Salix, in a deal valued at more than $10 billion.Allegan shares closed Friday at $178.00, a gain of $3.12, Valeant shares gained $1.19, to close at $128.99 and Salix closed down $4.56 at $161.77.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.